The effect of male sex on survival in systemic sclerosis

Journal of Rheumatology

Volumn 41, Issue 11, 2014, Pages 2193-2200

  Hussein, Haseena ^a,b   Lee, Peter ^a   Chau, Cathy ^c,d   Johnson, Sindhu R ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Mortality; Renal crisis; Scleroderma; Survival male sex; Systemic sclerosis

Indexed keywords

AZATHIOPRINE; CALCIUM CHANNEL BLOCKING AGENT; CENTROMERE ANTIBODY; CYCLOPHOSPHAMIDE; METHOTREXATE; SCL 70 ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; CALCINOSIS; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; ESOPHAGUS DISEASE; FEMALE; FINGER ULCER; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NAIL DISEASE; ONSET AGE; POSTMENOPAUSE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SEROLOGY; SEX DIFFERENCE; SEX RATIO; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC SCLEROSIS; TELANGIECTASIA; AGED; CANADA; COMPARATIVE STUDY; DISEASE COURSE; KAPLAN MEIER METHOD; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SURVIVAL;

ADULT; AGED; CANADA; CAUSE OF DEATH; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERTENSION, PULMONARY; KAPLAN-MEIER ESTIMATE; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SURVIVAL ANALYSIS;

EID: 84923247156     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.140006     Document Type: Article

References (62)

1. Ferri C, Valentini G, Cozzi F., Sebastiani M, Michelassi C, La Montagna G, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine 2002; 81:139-53.
2. Johnson SR, Glaman DD, Schentag C.T., Lee P. Quality of life and functional status in systemic sclerosis compared to other rheumatic diseases. J Rheumatol 2006; 33:1117-22.
3. Medsger TA Jr, Masi AT, Rodnan G.P., Benedek TG, Robinson H. Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med 1971; 75:369-76.
4. Silman AJ. Scleroderma and survival. Ann Rheum Dis 1991; 50:267-9.
5. Steen VD, Powell DL, Medsger TA. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988; 31:196-203.
6. Lu LJ, Wallace DJ, Ishimori M.L., Scofield RH, Weisman MH. Review: Male systemic lupus erythematosus: a review of sex disparities in this disease. Lupus 2010; 19:119-29.
7. Pennell LM, Galligan CL, Fish EN. Sex affects immunity. J Autoimmun 2012; 38:2-3.
8. Theis KA, Heimick CG, Hootman JM. Arthritis burden and impact are greater among U.S. women than men: intervention opportunities. J Womens Health 2007; 16:441-53.
9. Tan TC, Fang H, Magder L.S., Petri MA. Differences between male and female systemic lupus erythematosus in a multiethnic population. J Rheumatol 2012; 39:759-69.
10. Czirják L, Kumánovics G, Varjú C, Nagy Z, Pákozdi A, Szekanecz Z, et al. Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann Rheum Dis 2008; 67:59-63.
11. Hesseistrand R, Scheja A, Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 1998; 57:682-6.
12. Joven BE, Almodovar R, Carmona L., Carreira PE. Survival, causes of death, and risk factors associated with mortality in Spanish systemic sclerosis patients: results from a single university hospital. Semin Arthritis Rheum 2010; 39:285-93.
13. Kuo CF, See LC, Yu K.H., Chou IJ, Tseng WY, Chang HC, et al. Epidemiology and mortality of systemic sclerosis: a nationwide population study in Taiwan. Scand J Rheumatol 2011; 40:373-8.
14. Mayes MD, Lacey JV, Beebe-Dimmer J, Gillespie B.W., Cooper B., Laing TJ, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003; 48:2246-55.
15. Medsger TA, Masi AT. Survival with scleroderma. II. A life-table analysis of clinical and demographic factors in 358 male U.S. veteran patients. J Chronic Dis 1973; 26:647-60.
16. Peters-Golden M, Wise RA, Hochberg M.C., Stevens MB, Wigley FM. Carbon monoxide diffusing capacity as predictor of outcome in systemic sclerosis. Am J Med 1984; 77:1027-34.
17. Reveille JD, Fischbach M, McNearney T., Friedman AW, Aguilar MB, Lisse J, et al. GENISOS Study Group. Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum 2001; 30:332-46.
18. Silman AJ. Scleroderma - demographics and survival. J Rheumatol Suppl. 1997 May; 48:58-61.
19. Walker UA, Tyndall A, Czirják L, Denton C., Farge-Bancel D, Kowal-Bielecka O, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 2007; 66:754-63.
20. Wynn J, Fineberg N, Matzer L., Cortada X, Armstrong W, Dillon J.C., et al. Prediction of survival in progressive systemic sclerosis by multivariate analysis of clinical features. Am Heart J 1985; 110:123-7.
21. Kuwana M, Kaburaki J, Okano Y., Tojo T, Homma M. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 1994; 37:75-83.
22. Tyndall AJ, Bannert B, Vonk M., Airö P, Cozzi F, Carreira PE, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69:1809-15.
23. Farmer RG, Gifford RW, Hines EA. Prognostic significance of Raynaud's phenomenon and other clinical characteristics of systemic scleroderma. A study of 271 cases. Circulation 1960; 21:1088-95.
24. Al-Dhaher FF, Pope JE, Ouimet JM. Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum 2010; 39:269-77.
25. Wooten M. Systemic sclerosis and malignancy: a review of the literature. South Med J 2008; 101:59-62.
26. Burch PR, Rowell NR. Systemic lupus erythematosus: etiological aspects. Am J Med 1965; 38:793-801.
27. Derk CT, Rasheed M, Artlett C.M., Jimenez SA. A cohort study of cancer incidence in systemic sclerosis. J Rheumatol 2006; 33:1113-6.
28. Hachulla E, Carpentier P, Gressin V., Diot E, Allanore Y, Sibilia J., et al. Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study. Rheumatology 2009; 48:304-8.
29. Hill CL, Nguyen AM, Roder D, Roberts-Thomson P. Risk of cancer in patients with scleroderma: a population based cohort study. Ann Rheum Dis 2003; 62:728-31.
30. Rosenthal AK, McLaughlin JK, Gridley G, Nyrén O. Incidence of cancer among patients with systemic sclerosis. Cancer 1995; 76:910-4.
31. Bennett R, Bluestone R, Holt P.J., Bywaters EG. Survival in scleroderma. Ann Rheum Dis 1971; 30:581-8.
32. Aggarwal R, Lucas M, Fertig N., Oddis CV, Medsger TA. Anti-U3 RNP autoantibodies in systemic sclerosis. Arthritis Rheum 2009; 60:1112-8.
33. Graf SW, Hakendorf P, Lester S., Patterson K, Walker JG, Smith M.D., et al. South Australian Scleroderma Register: autoantibodies as predictive biomarkers of phenotype and outcome. Int J Rheum Dis 2012; 15:102-9.
34. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology /European League against Rheumatism collaborative initiative. Arthritis Rheum 2013; 65:2737-47.
35. Litle VR, Rice TW. The esophagus: do sex and gender matter? Semin Thorac Cardiovasc Surg 2011; 23:131-6.
36. Johnson SR, Granton JT, Tomlinson G.A., Grosbein HA, Le T, Lee P, et al. Warfarin in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. A Bayesian approach to evaluating treatment for uncommon disease. J Rheumatol 2012; 39:276-85.
37. LeRoy EC, Black C, Fleischmajer R., Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15:202-5.
38. Simonneau G, Robbins IM, Beghetti M, Channick R.N., Delcroix M., Denton CP, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54 Suppl 1 S43-54.
39. Pohar M, Stare J. Relative survival analysis in R. Comput Methods Programs Biomed 2006; 81:272-8.
40. Human Mortality Database. [Internet. Accessed September 4, 2014.] Available from: www.mortality.org, www.humanmortality.de
41. RStudio. RStudio: Integrated development environment for R. Version 0.97.248 ed. [Internet. Accessed September 5, 2014.] Available from: www.rstudio.com/products/rstudio/
42. Schuna AA. Autoimmune rheumatic diseases in women. J Am Pharm Assoc 2002; 42:612-23.
43. Roberts-Thomson PJ, Jones M, Hakendorf P., Kencana Dharmapatni AA, Walker JG, MacFarlane JG, et al. Scleroderma in South Australia: epidemiological observations of possible pathogenic significance. Intern Med J 2001; 31:220-9.
44. Jablonska S, Blaszcyk M. Connective tissue diseases. In: Parish LC, Brenner S, Ramos e Silva M, Parish JL, eds. Women's dermatology: from infancy to maturity. New York: Informa Healthcare; 2001:205-16.
45. Chifflot H, Fautrel B, Sordet C., Chatelus E, Sibilia J. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum 2008; 37:223-35.
46. Nguyen C, Bérezné A, Baubet T, Mestre-Stanislas C, Rannou F, Papelard A, et al. Association of gender with clinical expression, quality of life, disability, and depression and anxiety in patients with systemic sclerosis. PLoS One 2011; 6:e17551.
47. Piper WN, Helwig EB. Progressive systemic sclerosis; visceral manifestations in generalized scleroderma. AMAArch Derm 1955; 72:535-46.
48. Hissaria P, Lester S, Hakendorf P., Woodman R, Patterson K, Hill C., et al. Survival in scleroderma: results from the population-based South Australian Register. Intern Med J 2011; 41:381-90.
49. Hashimoto A, Tejima S, Tono T., Suzuki M, Tanaka S, Matsui T., et al. Predictors of survival and causes of death in Japanese patients with systemic sclerosis. J Rheumatol 2011; 38:1931-9.
50. Fransen J, Popa-Diaconu D, Hesselstrand R., Carreira P, Valentini G, Beretta L., et al. Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres. Ann Rheum Dis 2011; 70:1788-92.
51. Altman RD, Medsger TA, Bloch D.A., Michel BA. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 1991; 34:403-13.
52. Geirsson AJ, Wollheim FA, Akesson A. Disease severity of 100 patients with systemic sclerosis over a period of 14 years: using a modified Medsger scale. Ann Rheum Dis 2001; 60:1117-22.
53. Simeón CP, Castro-Guardiola A, Fonollosa V., Armadans L, Clemente C, Solans R., et al. Systemic sclerosis in men: clinical and immunological differences. Br J Rheumatol 1996; 35:910-1.
54. Bryan C, Knight C, Black C.M., Silman AJ. Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. Arthritis Rheum 1999; 42:2660-5.
55. Panopoulos ST, Bournia VK, Sfikakis PP. Is vasculopathy associated with systemic sclerosis more severe in men? J Rheumatol 2013; 40:46-51.
56. Krzyszczak ME, Li Y, Ross S.J., Ceribelli A., Chan EK, Bubb MR, et al. Gender and ethnicity differences in the prevalence of scleroderma-related autoantibodies. Clin Rheumatol 2011; 30:1333-9.
57. Selmi C, Invernizzi P, Gershwin ME. The X chromosome and systemic sclerosis. Curr Opin Rheumatol 2006; 18:601-5.
58. Migeon BR. The role of X inactivation and cellular mosaicism in women's health and sex-specific diseases. JAMA 2006; 295:1428-33.
59. Uz E, Loubiere LS, Gadi V.K., Ozbalkan Z., Stewart J, Nelson JL, et al. Skewed X-chromosome inactivation in scleroderma. Clin Rev Allergy Immunol 2008; 34:352-5.
60. Ozbalkan Z, Bagişlar S, Kiraz S., Akyerli CB, Ozer HT, Yavuz S, et al. Skewed X chromosome inactivation in blood cells of women with scleroderma. Arthritis Rheum 2005; 52:1564-70.
61. Johansson LA, Westerling R. Comparing hospital discharge records with death certificates: can the differences be explained? J Epidemiol Community Health 2002; 56:301-8.
62. Barnabe C, Bessette L, Flanagan C., Leclercq S, Steiman A, Kalache F., et al. Sex differences in pain scores and localization in inflammatory arthritis: a systematic review and metaanalysis. J Rheumatol 2012; 39:1221-30.